Page 174 - Read Online

Cheng et al. Advances in liver fibrosis

qualitative and quantitative comparison of gradient echo and spin non-alcoholic fatty liver disease. J Hepatol 2016;64:1388-402.
echo echoplanar imaging sequences. Invest Radiol 2016;51:575-81. 58. Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations
42. Huwart L, van Beers BE. MR elastography. Gastroenterol Clin Biol for testing, managing, and treating adults infected with hepatitis C
2008;32:68-72. virus. Hepatology 2015;62:932-54.
43. Sande JA, Verjee S, Vinayak S, Amersi F, Ghesani M. Ultrasound 59. Poynard T, Munteanu M, Deckmyn O, Ngo Y, Drane F, Messous D,
shear wave elastography and liver fibrosis: a prospective multicenter Castille JM, Housset C, Ratziu V, Imbert-Bismut F. Applicability and
study. World J Hepatol 2017;9:38-47. precautions of use of liver injury biomarker FibroTest. A reappraisal
44. Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive at 7 years of age. BMC Gastroenterol 2011;11:39.
quantitative assessment of hepatic steatosis and fibrosis in NAFLD 60. Poynard T, Lassailly G, Diaz E, Clement K, Caiazzo R, Tordjman
and NASH: clinical trials to clinical practice. J Hepatol 2016;65:1006- J, Munteanu M, Perazzo H, Demol B, Callafe R, Pattou F, Charlotte
16. F, Bedossa P, Mathurin P, Ratziu V, consortium F. Performance of
45. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients
Conjeevaram HS, Lok AS. A simple noninvasive index can predict with severe obesity: meta analysis of individual patient data. PLoS
both significant fibrosis and cirrhosis in patients with chronic hepatitis One 2012;7:e30325.
C. Hepatology 2003;38:518-26. 61. Salkic NN, Jovanovic P, Hauser G, Brcic M. FibroTest/Fibrosure for
46. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez- significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-
Bauer E, Bruguera M, Sanchez-Tapias JM, Rodes J. Identification analysis. Am J Gastroenterol 2014;109:796-809.
of chronic hepatitis C patients without hepatic fibrosis by a simple 62. Cales P, Boursier J, Oberti F, Hubert I, Gallois Y, Rousselet MC,
predictive model. Hepatology 2002;36:986-92. Dib N, Moal V, Macchi L, Chevailler A, Michalak S, Hunault G,
47. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Chaigneau J, Sawadogo A, Lunel F. FibroMeters: a family of blood
Dhalluin-Venier V, Fontaine H, Pol S. FIB-4: an inexpensive and tests for liver fibrosis. Gastroenterol Clin Biol 2008;32:40-51.
accurate marker of fibrosis in HCV infection. comparison with liver 63. Cales P, de Ledinghen V, Halfon P, Bacq Y, Leroy V, Boursier J,
biopsy and fibrotest. Hepatology 2007;46:32-6. Foucher J, Bourliere M, de Muret A, Sturm N, Hunault G, Oberti
48. Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki F. Evaluating the accuracy and increasing the reliable diagnosis
Y. FibroIndex, a practical index for predicting significant fibrosis in rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int
patients with chronic hepatitis C. Hepatology 2007;45:297-306. 2008;28:1352-62.
49. Hui AY, Chan HL, Wong VW, Liew CT, Chim AM, Chan FK, Sung 64. Cales P, Boursier J, Bertrais S, Oberti F, Gallois Y, Fouchard-Hubert
JJ. Identification of chronic hepatitis B patients without significant I, Dib N, Zarski JP, Rousselet MC; multicentric groups. Optimization
liver fibrosis by a simple noninvasive predictive model. Am J and robustness of blood tests for liver fibrosis and cirrhosis. Clin
Gastroenterol 2005;100:616-23. Biochem 2010;43:1315-22.
50. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, 65. Boursier J, de Ledinghen V, Zarski JP, Rousselet MC, Sturm N,
Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Foucher J, Leroy V, Fouchard-Hubert I, Bertrais S, Gallois Y, Oberti
Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD F, Dib N, Cales P. A new combination of blood test and fibroscan
fibrosis score: a noninvasive system that identifies liver fibrosis in for accurate non-invasive diagnosis of liver fibrosis stages in chronic
patients with NAFLD. Hepatology 2007;45:846-54. hepatitis C. Am J Gastroenterol 2011;106:1255-63.
51. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, 66. Loong TC, Wei JL, Leung JC, Wong GL, Shu SS, Chim AM, Chan
Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight AW, Choi PC, Tse YK, Chan HL, Wong VW. Application of the
patients. Gastroenterology 2000;118:1117-23. combined FibroMeter vibration-controlled transient elastography
52. Teshale E, Lu M, Rupp LB, Holmberg SD, Moorman AC, Spradling P, algorithm in Chinese patients with non-alcoholic fatty liver disease. J
Vijayadeva V, Boscarino JA, Schmidt MA, Gordon SC, Investigators Gastroenterol Hepatol 2017;32:1363-9.
CH. APRI and FIB-4 are good predictors of the stage of liver fibrosis 67. Armutcu F, Akyol S, Ucar F, Erdogan S, Akyol O. Markers in
in chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHeCS). nonalcoholic steatohepatitis. Adv Clin Chem 2013;61:67-125.
J Viral Hepat 2014;21:917-20. 68. Kaswala DH, Lai M, Afdhal NH. Fibrosis assessment in nonalcoholic
53. Kim WR, Berg T, Asselah T, Flisiak R, Fung S, Gordon SC, Janssen fatty liver disease (NAFLD) in 2016. Dig Dis Sci 2016;61:1356-64.
HL, Lampertico P, Lau D, Bornstein JD, Schall RE, Dinh P, Yee 69. Wong GL, Chan HL, Choi PC, Chan AW, Yu Z, Lai JW, Chan HY,
LJ, Martins EB, Lim SG, Loomba R, Petersen J, Buti M, Marcellin Wong VW. Non-invasive algorithm of enhanced liver fibrosis and liver
P. Evaluation of APRI and FIB-4 scoring systems for non-invasive stiffness measurement with transient elastography for advanced liver
assessment of hepatic fibrosis in chronic hepatitis B patients. J fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2014;39:197-
Hepatol 2016;64:773-80. 208.
54. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou 70. Parkes J, Roderick P, Harris S, Day C, Mutimer D, Collier J, Lombard
Y, Poynard T, Group M. Biochemical markers of liver fibrosis in M, Alexander G, Ramage J, Dusheiko G, Wheatley M, Gough C,
patients with hepatitis C virus infection: a prospective study. Lancet Burt A, Rosenberg W. Enhanced liver fibrosis test can predict clinical
2001;357:1069-75. outcomes in patients with chronic liver disease. Gut 2010;59:1245-51.
55. Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non- 71. Puigvehi M, Hernandez J, Broquetas T, Coll S, Garcia-Retortillo
invasive marker of liver fibrosis. Gastroenterol Clin Biol 2008;32:22- M, Canete N, Gimenez MD, Garcia M, Bory F, Salvado M, Sola
39. R, Carrion JA. Diagnostic accuracy of the enhanced liver fibrosis
56. European Association for Study of L, Asociacion Latinoamericana (ELF®) score using HCV-infected serum samples cryopreserved for
para el Estudio del H. EASL-ALEH Clinical Practice Guidelines: up to 25 years. PLoS One 2016;11:e0164883.
Non-invasive tests for evaluation of liver disease severity and 72. Wahl K, Rosenberg W, Vaske B, Manns MP, Schulze-Osthoff K,
prognosis. J Hepatol 2015;63:237-64. Bahr MJ, Bantel H. Biopsy-controlled liver fibrosis staging using
57. European Association for the Study of the L, European Association the enhanced liver fibrosis (ELF) score compared to transient
for the Study of D, European Association for the Study of O. EASL- elastography. PLoS One 2012;7:e51906.
EASD-EASO Clinical Practice Guidelines for the management of 73. Xie Q, Zhou X, Huang P, Wei J, Wang W, Zheng S. The performance
166 Hepatoma Research ¦ Volume 3 ¦ August 08, 2017